Browsing: Skye

San Diego-based Skye Bioscience, Inc. (Nasdaq: SKYE) and UK-based Redx Pharma Limited have agreed to combine in a transaction that will effectively give Redx’s fibrosis pipeline and management team a Nasdaq-listed vehicle, alongside approximately USD 125 million in concurrent financings. The combined company will operate as Fibrx Therapeutics, with existing Redx shareholders owning approximately 46.17%…